Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00916955 · ClinicalTrials.gov registry record
Genetic Modifiers for 22q11.2 Syndrome
A clinical trial, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
NCT00916955 is a clinical trial that has completed, run by State University of New York - Upstate Medical University.
The verdict
NCT00916955 has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
Study Summary
The purpose of the project is the determination of how the deletion of DNA from chromosome 22 at the q11.2 band causes the phenotypes observed in velo-cardio-facial syndrome (VCFS). In other words, the purpose remains genotype-to-phenotype matching. Current methods includes the use of whole genome chips and microarray analysis. Blood samples are collected for DNA from every patient who consents from the VCFS Center at Upstate Medical University. They are examined for phenotypic features consistent with our typical clinical evaluation. The information from these examinations will be entered anonymously into a database. Genomic information is then matched to clinical phenotype with appropriate statistical method applied.
Interventions
- OTHER Observation
Trial Details
| Field | Value |
|---|---|
| Start Date | 2008-03 |
| Est. Completion | 2015-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00916955
The ClinicalTrials.gov registry entry for NCT00916955 describes a study currently listed as completed, categorized as an unspecified phase. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Observation is the first listed.
NCT00916955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00916955 about?
NCT00916955 is a clinical study titled "Genetic Modifiers for 22q11.2 Syndrome". The purpose of the project is the determination of how the deletion of DNA from chromosome 22 at the q11.2 band causes the phenotypes observed in velo-cardio-facial syndrome (VCFS). In other words, the purpose remains genotype-to-phenotype matching. Current methods includes the use of whole genome c...
What is the current status of trial NCT00916955?
This trial is currently completed. The study started on 2008-03. Estimated completion is 2015-02.
What interventions are being tested in trial NCT00916955?
The interventions under investigation include: Observation (OTHER).
Who is sponsoring clinical trial NCT00916955?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.